Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration.
Recent developments may provide an opportunity to improve outcome in individuals who develop neovascular age-related macular degeneration (ARMD). Several therapies have been introduced that show promise for halting the progression of this disorder. However, data from controlled clinical trials to test the relative efficacy of different management strategies across the subtypes of disease remain limited. New treatment modalities that target the neovascularization process, including leakage from choroidal neovascularization (CNV), are currently being developed. Vascular endothelial growth factor (VEGF) has been implicated as a key mediator in the pathogenesis of ARMD-related CNV. Anti-VEGF strategies show promise as potential therapeutic agents for the treatment of CNV and are currently undergoing active clinical investigation. Such strategies include anti-VEGF antibodies, anti-VEGF aptamer, gene therapy and protein kinase C inhibition. This article reviews the mechanism of action and rationale for anti-VEGF drugs in ARMD.
Kim
Ramasamy
R
Retina Vitreous Services, Aravind eye Hospital, Madurai, India. kim@aravind.org
D020533:Angiogenesis Inhibitors / Q000493:pharmacokinetics*; D000818:Animals; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000378:metabolism; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A